Clinical trials: Hepatitis C Infections
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
- Trial name
- NCT00623428
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 235 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study.
- Trial name
- NCT01721265
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given…
- Trial name
- NCT00565539
- Testing
- PEGylated recombinant interleukin 29 (PEG-rIL-29)
- Where
- 11 sites in United States, Canada
- Volunteers
- 56 people
- Sponsor
- ZymoGenetics
Chronic HCV Infection
Phase 3 Study of Yimitasvir Phosphate Capsules
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT03487107
- Testing
- SOF, DAG181
- Where
- 35 sites in China
- Volunteers
- 362 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is, pegylated-interferon-alfa-2a and ribavirin in…
- Trial name
- NCT00580801
- Testing
- Telaprevir, Pegylated-interferon-alfa-2a, Ribavirin
- Volunteers
- 24 people
- Sponsor
- Tibotec BVBA
Hepatitis C
Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone
Otherwise healthy subjects who are currently bein maintained on either methadone or buprenorphine/naloxone for opioid maintenance therapy who have been on a stable dose for at least 30 days will be administered BI 201335 daily to…
- Trial name
- NCT01637922
- Testing
- BI 201335
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Boehringer Ingelheim
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Chronic Hepatitis c
Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C
This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the treatment of Chronic…
- Trial name
- NCT01903278
- Testing
- PEG-IFN-SA /RBV, Pegasys /RBV
- Where
- 41 sites in China
- Volunteers
- 719 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis C
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
The primary objective of this study is to describe the safety of the combination of Daklinza (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C (CHC) genotype 1b patients in real-life…
- Trial name
- NCT02727933
- Where
- South Korea
- Volunteers
- 1,941 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study…
- Trial name
- C-WORTHy (NCT01717326)
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 573 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.
- Trial name
- NCT02104843
- Testing
- Daclatasvir, Asunaprevir and BMS-791325 FDC, BMS-791325, Rosuvastatin
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Infections, Meningococcal
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™.
- Trial name
- NCT00291343
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY
- Where
- 2 sites in Philippines
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Virus
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
- Trial name
- NCT01581138
- Testing
- VX-222, telaprevir, ribavirin
- Where
- 18 sites in United States
- Volunteers
- 64 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
The purpose of this study is to evaluate the quality of the RNA and the reproducibility of gene expression profiling from liver tissue samples obtained by fine needle aspiration.
- Trial name
- NCT00828269
- Testing
- Comparator: Fine needle aspiration biopsy
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Hepatitis C
Drug-Drug Interaction Study in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone
- Trial name
- NCT00904059
- Testing
- BMS-650032, BMS-790052
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection
This multi-center, prospective observational study will evaluate the correlation of liver biopsy and transient elastography in liver fibrosis assessment in patients with chronic hepatitis C. Data will be collected for 96 weeks.
- Trial name
- NCT01671046
- Where
- 10 sites in Brazil
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.